title: What's New in Eyelid Tumors.
abstract: Eyelid malignancies represent between 5% and 10% of all skin cancers. Basal cell carcinoma is the most common, followed by squamous cell carcinoma, sebaceous cell carcinoma, Merkel cell carcinoma, and melanoma. The gold standard treatment for periocular epithelial malignancies is surgical excision. Given the constraints of the anatomy and function of the eyelids, excision with negative margins and reconstruction can be challenging. In cases of significant tissue invasion or metastasis, complete tumor removal may not be possible. This review examines the management of periocular skin cancer from diagnosis and staging, including the role of sentinel lymph node biopsy, to both surgical and nonsurgical treatment. The development of targeted drug therapy against specific genetic mutations in cutaneous malignancies has allowed for the treatment of specific cancer cells with less systemic toxicity than more traditional treatments.
authors.affiliation: Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, NY.
authors.forename: Nora
authors.initials: N
authors.lastname: Silverman
authors.affiliation: Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, NY.
authors.forename: Roman
authors.initials: R
authors.lastname: Shinder
mesh_terms: D003131:Combined Modality Therapy; D005142:Eyelid Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D014943:Global Health; D006801:Humans; D015994:Incidence; D009367:Neoplasm Staging; D011379:Prognosis
keywords: cancer; eyelid; malignancy